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THE host does not appear to produce an immune reaction against a spontaneous
tumour, or reacts too little and too late. Ifthe host could be sensitised against its
tumour a cure might result. The small lymphocyte is thought to play ani impor-
tant role in some hypersensitivity reactions (Landsteiner and Chase, 1942) and in
reactions against incompatible grafts (see Symposium edited by Medawar, 1963,
and Gowans, 1965, for reviews). We therefore studied protection against fatal
challenge with BP8 ascites tumour in C3H, or C3H/57 F1 mice, using lymphocytes
from C57B1 mice donors, injected with BP8 cells. alone or with Freund's complete
adjuvant. The F1 hybrid cross (C3H $ x C57B1 S) was used to avoid any rejec-
tion of the lymphocytes obtained from the " immunised " C57 donors. Later
we found that pure C3H mice behaved like the C3H/C57 F1 for the purpose of the
experiment.
METHODS
The BP8 tumour was maintained by serial passage in C3H mice. After 12
days the mice were killed by cervical dislocation, 1 ml. of Hank's solution and 5
units heparin/ml. were injected i.p. and the ascitic fluid removed under sterile
conditions. The cells were diluted with heparinised Hank's solution to an ap-
propriate concentration after a viable count had been made with Trypan Blue.
Immunisation procedures.-BP8 cells were counted and then " killed " by
rapid passage three times from liquid nitrogen to a 370 C. water bath. Phase-
contrast microscopy confirmed that all cells were dead. An identical method was
used for killing spleen and liver cells for Experiment 8.
Use of Freund's complete adjuvant (Difco).-In order to ensure intimate
mixing (without heat) freeze/thawed BP8 cell suspensions were emulsified with
Freund's adjuvant by repeated passage through 3 cm. of fine polythene tubing
tightly fitting between two tuberculin syringes with Luer-locked needles.
The details of the immunisation schedules are found in Tables I, IV and X in
conjunction with the appropriate experiments.
Preparation of lymphocytesfrom immuninsed (C57Bl mice
(1) " Hash " preparations of lymphoid cells.-Lymph nodes or spleen were
removed under sterile conditions, dissected free offat, minced with angled scissors
in a plastic or siliconised Petri dish and diluted with sterile Hanks' solution.
(2) Isolation from blood (modified from method of Skoog and Beck, 1956).-
Blood from cardiac puncture was heparinised (20 units/ml.), diluted with twice
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TABLE I. Immunisation Programme for C57Bl Mice (Part 1)
PILOT EXPERIMENTS: Two groups of C57B1 mice were injected accordingf
to the schedule in Table I. In all experiments lymphoid cell preparations
w%Aere taken one week after the previous immunising dose.
Groui) A without adjuvant Group B with adjuvaint
immunising dose of immunising dose of
killed BP8 cells killed BPS cells
Immuinising (loses Used in ,,- ----
given on day: experiment no. Intraperit. Intramusc. Intraperit. Intramuse.
* .- *. 9 x 106} 4 x106 . 1x 106 2x 106
83 I 1X106 I X1106 . 5x3x105 1xl06
94 1 . 1X 106 1 X 106 . 3x 105 1 x10(6
Ill 4x106 - - 4x108
Mice were injected either intraperitoneally or intramuscularly.
its volume of 400 Dextran 110 in saline, and left for 30 minutes at room tempera-
ture in a tube at an angle of450, with frequent inversions. This treatment yielded
the best size of rouleaux. The supernatant was filtered through 3 cm. of densely
packed glass wool in a sterile, siliconised Pasteur pipette (to remove polymorphs
and monocytes) and washed through with 3 to 4 ml. Hank's solution or TC 199.
The filtrate was centrifuged at 500 g. for 5 minutes and resuspended in 1 ml. of
Hank's solution or TC 199. Leishmann-stained smears showed that the white
cells were almost 100% small lymphocytes with considerable red cell contamina-
tion.
(3) Isolation from spleen (based on Janowsky, Rosenau. and Moon, 1964).-
Minced spleens from 2 mice were suspended in 5 ml. TC 199 and filteredthrough 2
layers of lint-free gauze. After centrifugation the packed cells were resuspended
in 10 nil. of unbuffered 0-35 00 saline to lyse the erythrocytes. After 1 minute the
salinity was restored by adding 1 2 ml. 500 saline. This process was repeated and
finally the cell suspension was spun and resuspended three times in TC 199. A
viable count showed that the lymphocytes survived this treatment very much
better than macrophages.
(4) Isolation from lymph nodes.-Lymph nodes were disrupted by mincing anld
pipetting in a little TC 199; the suspension was passed through a double layer of
fine muslin gauze, spun and washed twice with TC 199, and adjusted to the
appropriate viable cell concentration.
Lymphocyte preparations were made about 7 days after the last immunising
dose and mixed with 5 x 104 living BP8 cells just before injection i.p. except in
Experiment 5 when the lymphocytes were given i..p 24 hours after the tumour
cells. Mice were inspected daily and either weighed or the size of the abdomen
was recorded by a system of - to 6+ scoring. Day of death was noted, all mice
were autopsied and any tissues of interest were examined histologically.
RESULTS
Part I. Pilot Experiments
Protection of C3H/C57 F1 mice against fatal challenge with BP8 cells afforded by
"Lymphoid Cell " preparations, madefrom immunised C57 donor mice.
Experiment 1.-The results (Table II) showed that the unprotectedC3H/C57 F1
control mice died with ascites in 15 to 18 days. (In all experiments the mean
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survival of 19, C3H/C57 F1 control mice was 14-42 + 0 35 days). C3H/C57 F1
mice protected with lymph node or spleen hash, or with blood lymphocytes from
C57 mice immunised with 3 doses of BP8 cells alone (Table I, Group A) also died
in less than 20 days, but those protected by identical preparations made from
C57 mice immunised with BP8 cells plus Freund's adjuvant (Table I, Group B)
showed very significant protection.
TABLE II.
EXPERIMENT 1: "Lymphoid cell " preparations made from C57B1 mice
injected with 3 doses of BP8 cells did not protect C3H/C57F1 mice against
challenge with 5 x 104 BP8 cells i.p. Similar preparations made from C57B1
mice injected with BP8 cells and Freund's adjuvant gave good protection.
C3H/C57 F, mice all challenged with
5 x 104 living BP8 cells i.p.
Controls (no protection)
"Protected " with " lymphoid cell"
preparations from Group A, C57B1 mice
injected with 3 doses killed BP8 cells i.p.
Lymph node hash
Spleen hash
Blood lymphocytes (2 x 106)
"Protected " with " lymphoid cell"
preparations from Group B, C57B1 mice
injected with 3 doses BP8 cells + Freund's
adjuvant i.p.:
Lymph node hash . .
Spleen hash
Blood lymphocytes
* Experiment was terminated at 246 days, mice
seen.
Number of mice
surviving more
than 20 days
0/4
0/2
0/2
0/1
Survival times
(days)
15, 18, 18, 18
15, 20
19, 19
15
2/2 . 246*, 246*
2/2 . 89, 246*
1/1 . 25
,healthy and at autopsy no abnormalities were
TABLE III.
EXPERIMENT 2: " Lymphoid cell " preparations made from C57B1 mice
injected with 4 doses of killed BP8 cells or 4 doses of killed BP8 cells and
Freund's adjuvant gave protection against challenge with 5 x 104 BP8
cells i.p.
C3H/C57 F, mice all challenged with
5 x 104 living BP8 cells i.p.
Controls (no protection)
" Protection " with " lymphoid cell "
preparations from Group A, C57B1 mice
injected with 4 doses killed BP8 cells
intramuscularly:
Lymph node hash
Spleen hash
Number of mice
surviving more
than 20 days
0/7
Survival times
(days)
13, 14, 15, 15, 15,
15, 15
2/3 . 17, 228*, 228*
2/3 49, 228*, 228*
" Protected " with " lymphoid cell "
preparations from Group B, C57B1 mice
injected with 4 doses BP8 cells + Freund's
adjuvant intramusacularly:
Lymph node hash . . 3/3 . 23, 228*, 228*
Spleen . . . . . . 3/3 . 228*, 228*, 228*
Blood lymphocytes . . . 3/3 . 228*, 228*, 228*
* Experiment was terminated at 228 days, mice healthy and at autopsy no abnormalities were
seen.
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Experiment 2.-(Table III). When Experiment 1 was repeated very significant
protection was given by lymph node and spleen hash made from C57 mice which
had received 4 injections of freeze/thawed BP8 cells (Table I, Group A). This
protection was almost as good as that given by similar preparations made from
C57 mice which received injections of BP8 cells plus Freund's adjuvant.
Part 2. Quantitative Experiments to Find the Number of Viable Lymphocytes
Required to Protect Against Challenge by 5 X 104 Living BP8 Cells
For experiments 3-5 fresh groups of C57B1 mice were immunised according to
the schedules shown in Table IV, Groups C and D. Various doses oflymphocytes
prepared from spleen, or lymph nodes ofthese mice were used to protect C3H/C57
F1 mice or C3H mice against BPS cells.
TABLE IV'. Quantitative Experiments (Part 2). Immunisation Programnme
for C57Bl (Male and Female) Mice
Group E
Immunising Group C Group D Freund's
(sensitising) doses BP8 " killed " cells BP8 " killed " cells adjuvant Group I"
given on day: i.m. + Freund's adjuvant i.m. i.m. controls
(O Hind limbs Hind limbs Hind limbs -
3- 8 x 106 3-8 x 106+0- I ml. 0 I ml.
26 Hind limbs Hind limbs Hind limbs
3-8x 106 3 8x106+0m1 ml. 0- Iml.
33 Fore limbs Fore limbs Fore limbs
l9X 106 1-9x106+0-1 ml. 0-1 ml.
44 Fore limbs Fore limbs
3.8x106 3.8x106+0 Iml.
Exp. No. 3. on 55th day
Also frozen-stored cells for exp. 4.
Exp. No. 6. on 61st day
68 All limbs All limbs
4x106 -)x106+0-1 ml.
Exp. No. 4. oIn 75th day
93 BP8 Cells + Freund's
1 x 106+0*ml. 1 x 106+0*1 ml.
Exp. No. 5. oIn 100th day
Experiment 3.-(Table V). Protection by lymphocytes from C57 mice im-
munised with and without Freund's adjuvant (Table IV, Groups D and C respec-
tively) were compared quantitatively. Group C lymphocytes showed no
protection; group D lymphocytes showed slight protection at a dose of 2 x 105,
and significant protection at 8 x 105 and 3 X 106. Survival times were signi-
ficantly greater for animals treated with group D lymphocytes (" t " 5.4,
n = 22, p < 0.001).
Experiment 4 (Table VI). Lymphocytes prepared from spleens of mice
immunised as in Table IV, Group D, were cooled at 1°/min. in TC 199 plus 10%
methyl suphoxide, and stored for 20 days in liquid nitrogen. The ampoules
were rapidly thawed by immersion in a 40° C. water bath; after resuspending the
cells in TC 199 the viability was 70%O (Trypan blue counts). These frozen-stored
lymphocytes gave definite protection to C3H mice (Table VI, compare with
corresponding part of Experiment 3); The C3H controls survived somewhat
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TABLE V.
EXPERIMENT 3: 3 x 106 lymphocytes prepared from SPLEEN OR
LYMPH NODES OF C57B1 mice immunised 4 times with BP8 cells +
Freund's adjuvant gave protection against fatal challenge with BP8 cells.
Number of mice
C3H/C57 F1 mice all challenged with 5 x 104 surviving more Survival timcs
BP8 cells i.p. than 20 days (days)
Controls (not protected) males . 0/2 . 10, 12
females . 0/2 . 12, 15
"Protected " with Spleen lymphocytes from C57B1 mice
immunised with 4 doses of killed BP8 cells (Table IV,
Group C)
2 x 105 lymphocytes . 0/ . 14, 15
8 x 105 lymphocytes . 0/2 . 14, 14
4 5x 106 lymphocytes . 0/2 . 14, 14
"Protected " with Lymph Node lymphocytes from
C57B1 mice (Table IV, Group C)
2 x 105 lymphocytes 0/2 14, 14
8 x 105 lymphocytes . 0/2 . 14, 14
3 x 106 lymphocytes 0/2 14, 14
"Protected " with Spleen lymphocytes from C57B1 mice
immunised with 4 doses BP8 cells + Freund's adjuvant
(Table IV, Group D)
2 x 105 lymphocytes 0/2 . 15, 15
8 x 105 lymphocytes . 1/2 . 15, 28
3 x 106 lymphocytes . 1/2 16, 40
"Protected " with Lymph Node lymphocytes from C57B1
immunised with 4 doses BP8 cells + Freund's adjuvant
(Table IV, Group D)
2 x 105 lymphocytes . 0/2 . 16, 18
8x 105 lymphocytes . 1/2 . 15, 28
3 x 106 lymphocytes . 2/2 . 46, 154*
* Experiment was terminated at 154 days, mouse healthy and at autopsy no abnormalities were
seen.
longer than the C3H/C57 F1 controls: nevertheless the results suggest that the
frozen-stored lymphocytes had retained most of their activity. The survival
after protection with 1-4 x 106 freshly isolated lymphocytes was much better
than anticipated, possibly due to the use of C3H in lieu of C3H/C57 F1 mice, or
because the C57 donors received a fifth immunisation dose.
Experiment 5.-(Table VII). Lymphocytes from immunised C57 donors gave
considerable protection when injected into C3H mice 24 hours after challenge by
BP8 cells. However, protection appeared less complete than that given by fewer
lymphocytes injected at the same time as the tumour cells, possibly because the
tumour cells multiplied during the 24-hour delay and spread throughout the
peritoneal cavity.
It was considered that control mice might survive longer if the exudation of
ascitic fluid into the peritoneal cavity could be delayed. To test this, fluid intake
was restricted just before and during the onset of ascites. The mean survival of
the unprotected mice was increased from 15-2 to 19-25 days (" t "2.32, n = 7;
p = 0.06). However, the mean survival of all 8 water-restricted controls
(19.9 + 1-3 days) did not differ significantly from the mean of all 30 unprotected
C3H controls (17.6 ± 0-5 days); "tt "- 1-64, n = 36; 02- > p > 0 1.
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TABLE VI.
EXPERIMENT 4: Protection of C3H mice by frozen-stored lymphocytes
from Experiment 3, and by freshly prepared lymphocytes from C57B1 mice
injected with BP8 plus Freund's adjuvant.
C3H mice
All challenged with 5 x 104 BP8 cells i.p.
Controls. No protection
Protected with 2m 8 x 106 lymphocytes (from
Exp. 3) prepared from Spleen of C57 mice
injected with BP8 cells + Freund's adjuvant and
stored at -1800 C. for 20 days
Protected with lymphocytes prepared from lymph
nodes of C57 mice injected with 5 doses of
BP8 + Freund's adjuvant (Table IV Group D)
Lymphocytes 1 4 x 106
Lymphocytes 2 8 x 106
Number of mice
surviving more
than 20 days
0/6
8/10
10/10
10/10
Survival time
(days)
15, 16, 16; 17, 17,
20
18, 20, 21, 21, 24,
26, 26, 28, 233*,
233*
233*, 233*, 233*,
233*, 233*, 233*,
233*, 233*, 233*,
233*
233*, 233*, 233*,
233*, 233*, 233*,
233*, 233*, 933*,
233*
The frozen-stored lymphocyte gave some protection but this was not as good as that given by
freshly isolated lymphocytes from mice which had received another sensitising dose of BP8 +
Freund's adjuvant.
* Experiment terminated at 233 days, mice healthy and at autopsy no abnormalities were seen
(except for 1 mouse with a cyst on the liver).
TABLE VII.
EXPERIMENT 5: C3H mice injected with 5 x 104 BP8 cells i.p. on day 0.
Preparations ofpure lymphocytes given 24 hours later i.p. gave very significant
protection. The lymphocytes were made from the lymph nodes of C57 mice
immunised as shown in Table IV Group D.
C3H controls. 50,000 BP8 cells i.p., 24 hours later
0 33 ml. TC 199 i.p.
C3H controls. 50,000 BP8 cells i.p., 24 hours later
0 33 ml. TC 199, fluid restricted
C3H mice 50,000 BP8 cells i.p., 24 hours later
5-3 x 106 lymph node lymphocytes i.p., fluid
restricted
C3H mice. 50,000 BP8 cells, i.p., 24 hours later
5 - 3 x 106 lymph node lymphocytes i.p.
C3H mice. 50,000 BP8 cells i.p., 24 hours later
1 x 106 blood lymphocytes i.p.
Number of mice
surviving more
than 20 days
0/5
1/4
5/5
10/10
4/5
Survival time3
(days)
14, 15, 15, 16, 16
16, 18, 19, 24
26, 208t, 208t, 208t,
208t
30, 34*, 68, 97, 208t
208t, 208t, 208t,
208t, 208t
16, 30, 30*, 51,
208t
Five of the control mice and 5 of the experimental mice were fluid restricted on the 4th and 6th
day after the first injection.
Water restriction increased slightly the survival time of the controls.
* Did not die from tumour.
t Experiment terminated at 208 days, mice healthy and at autopsy no abnormalities were seen
(except for 1 mouse with a cyst in the peritoneum).
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Part 3. Control Experiments
C(ontrol experiments were necessary to exclude protection by:
(i) Allogeneic lymphocytes from non-immunised donors.
(ii) Cytophilic antibody.
(iii) Non-specific effects of Freund's adjuvant on lymphocytes.
(iv) A non tumour-specific mechanism, e.g. if BP8 cells simply acted as a
source of C3H histocompatibility antigens then immunisation of C57 mice
with C3H spleen and liver cells (rich in H2antigens) should also be effective.
(v) & (vi) Isogeneic lymphocytes fron C3H donor mice (immunised with BP8
cells or BP8 cells plus Freund's adjuvant).
(vii) Direct immunisation of C3H mice with dead BP8 cells plus Freund's
adjuvant before challenge with living BP8 tumour cells.
Experiment 6. (Table VIII), designed to test possibilities (i), (ii) and (iii).
(i) 3 x 106 lymphocytes from normal. non-immunised C57 mice (Table IN,
(Group F) gave no protection.
TABLE VIII. Control Experiments (Part 3)
EXPERIAMENT 6 To exlude protection by:-
(i) Lymphocytes from normal C57B1 mice
(ii) Lymphocytes from normal C57B1 mice incubated with serum from C57B1
mice sensitised with BP8 cells and Freund's adjuvant.
(iii) Lymph node or spleen hash from C57B1 mice injected with Freund's adjuvant
alone.
Number of mice
C3H/C.57 F1 (male) mice challenged with 5 x 104 surviving more Survival time
BP8 cells i.p. than 20 days (days)
(i) " Protected " with 3 x 106 lymphocytes from 0/4 11, 12, 12, 13
inormal C57B1 mice (See Table IV, Group F.)
(ii) "Protected " with 2-5 X 106 lymphocytes (from 0/5 13. 13, 13, 14, 14
normal C57BI mice) which had been incubated at
37° C. for 30 min. with 1 ml. of serum from C57Bl
mice sensitised with 4 doses of BP8 cells + Freund's
adjuvant (See Table IV, Group D)
(iii) " Protected " with lymphoid preparations made
from C57BI mice injected with 3 x 0.-1 ml. of
Freuind's adjuvant alone (See Table IV, Group E)
Spleen Hash 0/2 14, 18
Lymph Node Hash 0/2 16, 16
(ii) Normal C57 lymphocytes, incubated with serum from C57 mice (im-
munised as in Table IV, Group D) and injected into C3H/C57 F1 mice,
give no protection.
(iii) Hash preparations from C57 mice injected with Freund's adjuvant alone
(Table IV, Group E) were injected into C3H/C57 F1 mice challenged with
BP8 cells i.p.; although survival times were significantly longer than the
control group, they were not significantly longer than the mean survival
time of all the C3H/C57 F1 control groups. The protection afforded was
not in the same order of magnitude as that given by lymphoid cell or
lymphocyte preparations from C57 mice injected with both BP8 cells and
Freund's adjuvant (see Experiments 1 to 5).
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TABLE IX.-C4ontrol Experiments (Part 3)
EXPERIMENT 7 To exclude protection by:-
(iv) Lymphocytes from C57B1 mice injected with 16 x 106 disrupted C3H
spleen and liver cells +01 ml. Freund's adjuvant on day 0, and 6 x 106
+01 ml. Freund's adjuvant on day 11. Lymphocytes taken on day 18.
Survival time
Number of mice (days)
C3H/C57 F, mice challenged with surviving more
5 x 104 BP8 cells i.p. than 20 days male female
r-ols no " lprotection " 0/4 . 10. 12 15, 15
Protected with lymphocytes from C57 mice injected -with
2 doses C3H spleen & liver cells in Freund's adjuvant
8 x 105 lymphocytes
1- 6 x 106 lymphocytes
3-2 x 106 lymphocytes
6 4 x 106 lymphocytes
0/4
0/4
0/4
0/4
10, 1(
10, 11
13, 13
12, 13
15, 15
13, 13
14, 14
13, 13
(iv) Experiment 7. (Table IX), to test possibility (iv). C3H spleen and
liver cells, rich in histocompatibility antigens, were injected in large doses
with Freund's adjuvant into C57 mice. Lymphocytes from these mice
(even in doses of 6-4 x 106) gave no protection to C3H/C57 F1 mice.
Experiment 8.-(Table XI), designed to test possibilities (v) and (vi). Two
groups of 6 male C3H mice were immunised with BP8 cells alone or with Freund's
adjuvant (Table X. Groups G and H). Two mice from each group were used to
prepare lymph-node and spleen hash preparations for injection into C3H mice.
No protection against BPS cells was observed.
TABLE X.-Immunisation Programmefor C(3H (Male) Mice
Immunising (sensitising) (loses
given on day:
7
14
Group G Group H
BP8 " killed " cells i.m. BP8 cells + Freund's
adjuvant i.m.
All 4 limbs All 4 limbs
7.2 X106 3 6X106+0.2mi.
All 4 limbs All 4 limbs
3 8x106 1 9x 106+0 1 ml.
All 4 limbs All 4 limbs
68x106 3 4x106+0 I ml.
- mice in each group were used to prepare
Spleen and Lymph Node Hash for Exp.
8 on 23rd day
4 mice in each group were challenged with
5 x 104 living BP8 cells i.p. on (lay
60-Exp. 10
Experiments 9 and 10 were designed to test possibility (vii).
Experiment 9.- (Table XII). BP8 cells. killed by freeze/thawing and injected
with Freund's adjuvant into C3H mice, 23 days before challenge with 105 live
BP8 cells, gave no protection. A second group of C3H mice were " immunised "
with dead BP8 cells plus Freund's adjuvant on day 0 and again on day 23. After
challenge with live BP8 cells on day 37 they died with ascites tumour rather more
CoInt
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TABLE XI.-Control Experiments (Part 3)
EXPERIMENT 8 To exclude protection by:-
(v) Lymphoid cell preparations from C3H mice previously immunised witl
BP8 cells.
(vi) Lymphoid cell preparations from C3H mice previously immunised with BP8
cells + Freund's adjuvant.
C3H mice (male) challenged with
5 x 104 BP8 cells i.p.
Controls no protection
(v) " Protected " with lymphoid cell
preparations from C3H mice injected 3
times with killed BP8 cells (see Table
X, Group G)
Lymph Node Hash
Spleen Hash
(vi) " Protected " with lymphoid cell
preparations from C3H mice injected
3 times with killed BP8 cells + Freund's
adjuvant (see Table X, Group H)
Lymph Node Hash
Spleen Hash
Number of mice
surviving more
than 20 days
Survival time
(days)
0/5 . 17, 19, 19, 19, 19
0/2 16, 16
0/2 . 16, 17
0/2 17, 17
0/2 . 17, 18
TABLE XII.-Control Experiments (Part 3)
EXPERIMENT 9 To exclude protection by:-
(vii) Direct immunization ofC3H mice with killed BP8 cells + Freund's adjuvant
before challenge with living BP8 cells i.p.
C3H mice (female) all challenged with
1 x 105 BP8 cells i.p.
Normal C3H mice
C3H mice " injected " with 8 x 106 killed
BP8 cells + 0 1 ml. Freund's adjuvant
23 days before challenge
Normal C3H mice
C3H mice injected with 8 x 106 killed
BP8 cells + 0 1 ml. Freund's on day 0
and 105 killed BP8 + 041 ml. Freund's
adjuvant on day 23 challenged on day 37
Number of mice
surviving more
than 20 days
2/5
Survival time
(days)
. 15, 16, 17, 21, 26
0/6 . 14, 14, 16, 17, 17, 17
1/5 . 16, 17, 17, 20, 23
0/6 . 11, 11, 12, 12, 13,
14
quickly than the controls. This early experiment, in collaboration with Pro-
fessor R. R. A. Coombs, forced us to consider the possibilitythatifthe outpouring
of plasma into the peritoneal cavity could be delayed, then the animals own
immune mechanisms would be given a better chance of dealing with the tumour
cells.
Experiment 10.-(Table XIII). 8 C3H mice (immunised as in Table X,
Groupings G and H) were challenged with 5 x 104 BP8 cells i.p., but fluid intake
was restricted on the 3rd, 5th and 10th day. The C3H mice injected with BP8
cells alone survived slightly longer than expected, but those immunised with BP8
plus Freund's adjuvant showed definite protection.
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TABLE XIII-Control Experiments (Part 3)
EXPERIMENT 10
(viii) Further study of the effect of pre-immunising C3H mice with killed BP8
cells (with or without Freund's adjuvant) and the effect of control of
ascitic fluid formation by periods of fluid restriction on survival after
challenge with living BP8 cells i.p.
Number of mice
C3H male mice, challenged with surviving more Survival time
5 x 104 BP8 cells i.p. than 20 days (days)
Normal C3H controls, fluid restricted on 0/4 16, 17, 18, 19
3rd day, 5th day and 10th day
Immunised with killed BP8 cells, 3 doses 2/4 . 15, 19, 24, 24
(see Table X Group G) fluids
restricted as above
Immunised with killed BP8 cells + 3/4 . 17, 28, 223*, 223*
Fieund's adjuvant, 3 doses (see Table
X Group H) fluid restricted as above
* Experimeint terminated at 223 days, mice healthy an(L at autopsy no abnormalities were seen.
DISCUSSION
Experiments 1 to 5 clearly showedthat lymphocytes from C57 mice (immunised
with BP8 cells plus Freund's adjuvant) gave definite protection to C3H/C57 F1
or C3H mice against fatal challenge with BP8 tumour cells. However, certain
technical points and alternative explanations should be considered.
We have reason to believe that the BP8 tumour is isogeneic with C3H mice.
It was induced by benzopyrene in this strain and as few as 100 cells are said to
be 1000% lethal. We have not titrated it but we have used doses down to 6 x 103
with complete success; 5 X 104 cells was chosen as a big dose and was fatal in
unprotected C3H/C57 F1 mice in under 20 days. We always challenged with
freshly isolated cells to avoid the uncertainties involved in using cells stored in
liquid nitrogen. However, both the tumour and the inbred mice can of course
vary during repeated passage. Whenever possible the lymphocytes were isolated
7 days after the last immunising dose since lymphocyte immune-activity is
maximal at this time whereas humoral-antibody titres are still low (Brondz, 1964).
This was the reason for our schedule of repeated injections in preparing the C57
lymphocyte donors. In order to avoid damaging their antigenic structure, BP8
cells were killed by freeze/thawing, and intimate mixing with Freund's adjuvant
was aclhieved without heat development by the emulsification techniques we
employed. Some difficulty was experienced in isolating lymphocytes from the
small quantity of blood available from mice. Care was taken to use non-wettable
plastic or siliconed-glass apparatus. Viable counts showed good recovery of
lymphocytes, practically free from other white cells, but with some red cell
contamination.
The mixing of living BP8 cells with lymphocyte preparations just before
injection i.p. appeared to have no deleterious effect on the BP8 cells, since the
challenged animals invariably died, unless the lymphocytes were from allogeneic,
and adequately immunised donors. Also " competent " lymphocytes gave
protection when injected 24 hours after the tumour dose. Kidd and Toolan
(1950) found a marked inhibition of tumour growth when susceptible mice were
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injected with pre-incubated mixtures of lymphoma cells anid minced lymph niodes
from mice with regressed lymphoma. However, Winn (1961), using sarcoma
(Sal), found that incubation of cell mixtures before injection into host mice had
no effect on the level of activity observed and concluded that the two cell typ)es
did not react in vitro. Indeed, the results obtained by Kidd and Toolan (195(i)
could have been due to the activity of the lymphocytes in vivo.
The spleen and lymph node hash used in our preliminary experiments wvould
have contained other cells besides lymphocytes. Bennett (1965) has shown
specific suppression of tumour growth by isolated peritoneal macrophages from
immunised mice, but these were less effective than the lymphocytes from the same
peritoneal exudates. Also Gough, Elves and Israels (1965) have shown that
macrophages can develop from lymphocytes in vitro (in the presence of poly-
morphs). Our experiments indicated that blood lymphocyte preparations had
most anti-tumour activity, on a per-cell basis, and the number of macrophages
in these preparations must have been very small. The evidence in favour of the
lymphocyte being the cell involved, accumulated since the pioneer work of Land-
steiner and Chase (1942), Billingham. Brent and Medawar (1954) and Mitchisoi
(1955) now appears very strong.
Certain alternative explanations of the destruction of tumour cells by 'coln-
petent" lymphocytes seem to be eliminated by the experiments described in
Part 3 of the results.
(i) There is no evidence of any non-specific activity of allogeneic lymphocytes
from non-immunised donor C57 mice against BP8 cells. We found no sign of
runt disease in any long-term survivors, so we have no indication that allogeneic
C57 donor lymphocytes acted against the host C3H/C57 F1 or C3H mice.
(ii) Bubenik and Koldovsky (1964) have shown that anti-tumour immunity
can be transferred with serum, and Stuck. Boyse, Old and Carswell (1964) found
cytophilic antibody present in several types of mouse leukaemia. However, we
do not believe that humoral antibody or cytophilic antibody (Boyden, 1963) can
explain the antitumour activity of our lymphocyte preparations because they
were all well washed in TC 199 and the only possible transfer ofy globulin would
be that absorbed on to any red cells present. Also in experiment 6 (ii), 1 ml. of
serum froin mice (whose lymphocytes gave good protection) gave no protection
when incubated with normal lymphocytes and the combination was injected i.p.
The findings of Algire, Weaver and Prehn (1957), that homografts in millipore
diffusion chambers survived if no cells could get through the pores, also discount
the role of cytophilic antibody.
(iii) We obtained definite evidence (Experiments 1 and 5) that lymphocytes
from C57 mice treated with BP8 cells plus Freund's adjuvant gave better anti-
tumour protection than lymphocytes from mice immunised with BP8 cells alone.
However, lymphocytes from mice injected with Freund's adjuvant alone (Experi-
ment 6, iii) failed to give any long-term survivors. Thus Freund's adjuvant
alone did not produce any useful non-specific enhancement oflymphocyte activity
against H2 histocompatibility antigens on the BP8 cells.
(iv) It also seemed unlikely that BP8 cells were simply serving as a source of
H2 histocompatibility antigens (Haughton, 1964), since lymphocytes could not be
sensitised by large doses of C3H spleen and liver cells plus Freund's adjuvant
(Experiment 7). It is possible that we failed to sensitise the C57 mice to C3H
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spleen and liver cells even though we used large doses and these cells are known to
" abound" in most of the important H2 histocompatibility antigens. It seems
more likely that the BP8 cells have a tumour-specific antigen.
(v) (vi) (vii) (viii). Foley (1953), Prehn and Main (1957), Prehn (1960), Kleiin
and Sjogren (1960), Tuffrey and Batchelor (1964), Moller (1964) and others have
shown that chemically induced mouse tumours were capable of immunising
isogeneic mice. Zilber and Gamaleya (1957). using anaphylactic reactions,
found evidence of tumour-specific antigens (see also Old and Boyse, 1964, for a
review of virus-induced tumours and specific antigens). If BP8 has a tumour-
specific antigen then it should be possible to immunise C3H mice against it.
We fail to show protection with lymphocytes from C3H donors which had beeil
immunised with BP8 cells plus Freund's adjuvant (Experiment 8); and our first
attempt to immunise C3H mice against direct challenge with living BP8 cells
also failed (Experiment 9). However, theresults ofExperiment 10 were in favour
of a tumour-specific antigen, since C3H mice injected with BP8 cells plus Freund's
adjuvant could resist challenge with living BP8 cells if the formation of ascitic
fluid was controlled by restriction of fluid intake. However, the tumour had
been passaged for nearly 9 months and changes in the histocompatibility antigens
could have occurred in tumour and host.
We think the activity of the sensitised small lymphocytes against the tumour
cell merits further study, in particular with regard to the mechanisms by which the
lymphocyte damages the tumour cell. With more knowledge it might be possible
to use allogeneic, anti-tumour competent lymphocytes as a therapeutic agent in
human cancer.
SUMMARY
C3H/C57 F1 mice or C3H mice were protected by lymplhocytes taken from
(57 mice (injected with freeze/thawed BP8 cells plus Freund's complete adjuvant)
against fatal challenge by living BP8 cells given i..p
These lymphocytes would also protect ifinjected i.p. 24 lhours after the tumour
cells.
In control experiments no protection was given by lymphocytes taken from
non-immunised C57 mice, or those injected with C3H liver and spleen cells plus
adjuvant, or adjuvant alone.
Some protection against challenge with BP8 cells was seen in C3H mice pre-
immunised with BP8 cells and Freund's adjuvant, but only when fluid intake was
restricted about the time of the onset of ascites.
We wish to thank Professor R. R. A. Coombs for lhelp and advice, and Dr.
L. B. Fraser for help in preparing the manuscript.
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